Deep Track Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Deep Track Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-48,280	Closed	-$5.94M	–	73
2023 Q4	$5.94M	Sell	48,280 -1,089,765	-96%	-$136M	0.2%	57
2023 Q3	$147M	Sell	1,138,045 -111,955	-9%	-$14.9M	5.69%	2
2023 Q2	$155M	Buy	1,250,000 +50,000	+4%	+$6.73M	7.17%	1
2023 Q1	$176M	Buy	1,200,000 +326,447	+37%	+$48.3M	7.21%	1
2022 Q4	$139M	Buy	873,553 +12,553	+1%	+$1.84M	5.84%	3
2022 Q3	$115M	Buy	861,000 +361,000	+72%	+$54.9M	5.26%	2
2022 Q2	$78M	Sell	500,000 -17,051	-3%	-$2.62M	5.13%	4
2022 Q1	$80.5M	Buy	517,051 +17,051	+3%	+$2.47M	5.16%	4
2021 Q4	$63.7M	Buy	+500,000	New	+$65.7M	4.5%	5

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deep Track Capital's JAZZ Position: Q1 2024 in Review

Deep Track Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 48,280 shares — an estimated $5.94M sold.

Deep Track Capital first reported a position in JAZZ in Q4 2021 and held it in 9 quarters. The position peaked at $176M in Q1 2023. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Deep Track Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Deep Track Capital sold 48,280 Jazz Pharmaceuticals shares in Q1 2024, an estimated $5.94M.
Deep Track Capital first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Deep Track Capital's Jazz Pharmaceuticals position peaked at $176M in Q1 2023.
480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.